Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
本文未提供摘要,请点击“查看全文”查看完整内容。